Psyomics secures £4M to revolutionise mental health assessment with AI

June 5, 2024

Psyomics, a UK-based mental health technology company, has secured £4 million in fresh funding.

This £4 million funding shows the commitment of the company towards improving lifespan mental health in the UK, by focusing on earlier diagnosis and effective intervention for mental health conditions in younger generations. Given that bipolar disorder is commonly misdiagnosed as major depressive disorder, Psyomics also secured the international exclusive license on the world’s first intellectual property for improving the diagnosis of this condition through a biomarker panel.

Dr Melinda Rees, CEO of Psyomics, said: “Mental health services continue to be in a challenged state in the UK and globally, with people waiting far too long for treatment. Censeo cuts waiting lists by reducing the administrative time burden, streamlining assessment processes and freeing up clinical time for healthcare professionals to spend treating patients. With these funds we can advance our platform, crucially developing a service for children, young people and their families and carers, expanding our reach so more people are able to get help sooner. Since Covid there has been an alarming downturn in children’s mental health, with record numbers of families seeking support. It is in everyone’s best interests to get these families the help they so desperately need and deserve.”

Other news stories